Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. IntelliPharmaCeutics International's selling, general, & admin. expense for the
three
months ended in Aug. 2023 was $0.19 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Aug. 2023 was $0.78 Mil.
IntelliPharmaCeutics International (OTCPK:IPCIQ) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
IntelliPharmaCeutics International Selling, General, & Admin. Expense Related Terms
IntelliPharmaCeutics International Selling, General, & Admin. Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IntelliPharmaCeutics International Selling, General, & Admin. Expense Chart
IPCIQ vs CHRO, KTTA, FRTX: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, IntelliPharmaCeutics International's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IntelliPharmaCeutics International Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where IntelliPharmaCeutics International's Selling, General, & Admin. Expense falls into.
IntelliPharmaCeutics International Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of $0.78 Mil mean?
IntelliPharmaCeutics International (IPCIQ) has a Selling, General, & Admin. Expense of $0.78 Mil as of Aug. 2023. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on IntelliPharmaCeutics International and its competitors.
Is IntelliPharmaCeutics International's Selling, General, & Admin. Expense too high?
IntelliPharmaCeutics International's current Selling, General, & Admin. Expense is $0.78 Mil. Overall, IntelliPharmaCeutics International has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does IntelliPharmaCeutics International's Selling, General, & Admin. Expense compare to CHRO and KTTA?
IntelliPharmaCeutics International's Selling, General, & Admin. Expense of $0.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on IntelliPharmaCeutics International and its competitors. IntelliPharmaCeutics International's current Selling, General, & Admin. Expense is $0.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IntelliPharmaCeutics International stock overvalued right now?
IntelliPharmaCeutics International (IPCIQ) has a current Selling, General, & Admin. Expense of $0.78 Mil. The current Selling, General, & Admin. Expense is $0.78 Mil. IntelliPharmaCeutics International's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For IntelliPharmaCeutics International (IPCIQ), the current Selling, General, & Admin. Expense is $0.78 Mil as of Aug. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline.
16GF Score
Get the complete analysis for IPCIQ
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPCIQ has been successfully added to your 
